507094049 01/26/2022

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7140886

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
FAYCAL TOUTI	09/09/2021
WENDY WINCKLER CAZANAVE	09/09/2021
SOPHIE CAZANAVE	09/09/2021
MEHAR CHEEMA	09/09/2021
ROBERT S. LANGER	09/09/2021

RECEIVING PARTY DATA

Name:	GLYMPSE BIO, INC.
Street Address:	35 CAMBRIDGEPARK DRIVE, SUITE 100
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02140

PROPERTY NUMBERS Total: 3

Property Type	Number
Application Number:	17573110
Application Number:	17573123
Application Number:	17573129

CORRESPONDENCE DATA

Fax Number: (650)493-8311

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 650-493-9300

Email: patentdocket@wsgr.com, lfralick@wsgr.com
Correspondent Name: WILSON SONSINI GOODRICH & ROSATI

Address Line 1: 650 PAGE MILL ROAD

Address Line 4: PALO ALTO, CALIFORNIA 94304-1050

ATTORNEY DOCKET NUMBER:	61226-702.501; 502; 503
NAME OF SUBMITTER:	YINGJIAO WANG
SIGNATURE:	/Yingjiao Wang/
DATE SIGNED:	01/26/2022

PATENT REEL: 058769 FRAME: 0659

507094049

Total Attachments: 6

 $source = 61226-702.501-702.502-702.503 - Assignment (signed) \ 4875-7528-9867 \ v.1\#page1.tif \\ source = 61226-702.501-702.502-702.503 - Assignment (signed) \ 4875-7528-9867 \ v.1\#page2.tif \\ source = 61226-702.501-702.502-702.503 - Assignment (signed) \ 4875-7528-9867 \ v.1\#page3.tif \\ source = 61226-702.501-702.502-702.503 - Assignment (signed) \ 4875-7528-9867 \ v.1\#page4.tif \\ source = 61226-702.501-702.502-702.503 - Assignment (signed) \ 4875-7528-9867 \ v.1\#page5.tif \\ source = 61226-702.501-702.502-702.503 - Assignment (signed) \ 4875-7528-9867 \ v.1\#page6.tif \\$

PATENT REEL: 058769 FRAME: 0660

PATENT ASSIGNMENT

Docket Number

61226-702.601

The undersigned:

- Faycal TOUTI
 103 Beech Street, Apt. 3
 Belmont, MA 02147
- Wendy Winckler ADAMOVICH 62 Country Club Road Melrose, MA 02176
- Sophie CAZANAVE
 88 Standish Street, Apt. 2
 Cambridge, MA 02138
- Mehar CHEEMA 150 River's Edge Drive, Apt. 174 Medford, MA 02155

Robert S. LANGER
 98 Montvale Road
 Newton, MA 02459

(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Glympse Bio, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 35 Cambridgepark Drive, Suite 100, Cambridge, MA 02140, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

EX VIVO PROTEASE ACTIVITY DETECTION FOR DISEASE DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT

for which a PCT application will be filed on or before <u>September 11, 2021</u> in the U.S. Receiving Office of the Patent Cooperation Treaty which will claim priority to U.S. Provisional Application No. <u>63/077,525</u> filed <u>September 11, 2020</u>

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation-in-part; non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

- 2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.
- 3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, , cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.
- 4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.
- 5. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
- 6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
- 7. This instrument will be interpreted and construed in accordance with the laws of the State of Massachusetts, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

	PATENT ASSIGNMENT	Docket Number	61226-702.601
Date: 03/09/11	Faycal TOUTT's Signature		
Date: 09/09/2\	Wendy-Wanckler ADAMOVICH's Signature		
Date: 09 (09)21	Sophie OAZANAVE's Signature		
Date 09/09/21	Mehar CHEEMA's Signature		
Date:	Robert S. LANGER's Signature		991
RECEIVED AND AGRE	ED TO BY ASSIGNEE: Glympse Bio, Inc.		
Date:	Signature: Name: Caroline Loew Title: Chief Executive Officer		

PATENT ASSIGNMENT

Docket Number

61226-702.601

The undersigned:

- Faycal TOLITI
 103 Beech Street, Apr. 3
 Belmont, MA 02147
- Wendy Winckler ADAMOVICH
 62 Country Club Road
 Metrose, MA 02176
- Sophie CAZANAVE
 88 Standish Street, Apt. 2
 Cambridge, MA 02138
- Mehar CHEEMA
 150 River's Edge Drive, Apt. 174
 Medford, MA 02155

Robert S, LANGER
 98 Montvale Road
 Newton, MA 02459

(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Glympse Bio, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 35 Cambridgepark Drive, Suite 100, Cambridge, MA. 02140. (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

EX VIVO PROTEASE ACTIVITY DETECTION FOR DISEASE DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT

for which a PCT application will be filed on or before <u>September 11, 2021</u> in the U.S. Receiving Office of the Patent Cooperation Treaty which will claim priority to U.S. Provisional Application No. <u>63/077.525</u> filed <u>September 11, 2020</u>

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (f) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

- 2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assigner the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said inventor(s) (the "<u>Inventions</u>") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, mysities, and damages of whatever nature recoverable from an infringement of the Assigned Patents.
- 3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents, (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions: provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.
- 4. The terms and covenants of this assignment shall inure to the benefit of said Assignce, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.
- Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
- 6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
- 7. This instrument will be interpreted and construed in accordance with the laws of the State of Massachusetts, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

	PATENT ASSIGNMENT	Docket Number 61226-702.601	
Date:	Fayond TOUTT's Signature		
Date:	Wendy Winckler ADAMOVICTI's Signature		
Date:	Sopbie CAZANAVE's Signature		
Dote	Mehar CHEEMA's Signature		
Date: 7-7-21	Roben S. LANGER's Signature		
RECEIVED AND A	GREED TO BY ASSIGNEE: Glympse Bio, Inc.		
Date:	Signature: Name: Caroline Loew Title: Chief Executive Officer		

PATENT ASSIGNMENT

Docket Number

61226-702.601

The undersigned:

- Faycal TOUTI
 103 Beech Street, Apt. 3
 Belmont, MA 02147
- Wendy Winckler
 Country Club Road Melrose, MA 02176
- Sophie CAZANAVE
 88 Standish Street, Apt. 2
 Cambridge, MA 02138
- Mehar CHEEMA 150 River's Edge Drive, Apt. 174 Medford, MA 02155

 Robert S. LANGER 98 Montvale Road Newton, MA 02459

(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Glympse Bio, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 35 Cambridgepark Drive, Suite 100, Cambridge, MA 02140, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

EX VIVO PROTEASE ACTIVITY DETECTION FOR DISEASE DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT

for which a PCT application will be filed on or before September 11, 2021 in the U.S. Receiving Office of the Patent Cooperation Treaty which will claim priority to U.S. Provisional Application No. 63/077.525 filed September 11, 2020

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

- 2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.
- 3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.
- 4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.
- 5. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
- 6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
- 7. This instrument will be interpreted and construed in accordance with the laws of the State of Massachusetts, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

	PATENT ASSIGNMENT	Docket Number	61226-702.601
Date:	Faycal TOUTI's Signature		
Date:	Wendy Winckler's Signsture		
Date:	Sophie CAZANAVE's Signature		
Date:	Mehor CHEEMA's Signature		
Date:	Robert S. LANGER's Signature		
Date: 9/1/201	ED TO BY ASSIGNED Glympse Bio, Inc. Signature: Name: Caroline Loew Title: Chief Executive Officer		

RECORDED: 01/26/2022